Endo International plc (OTC: ENDPQ), an American-Irish specialty pharmaceutical company, announced on Wednesday that its subsidiary Endo Ventures Limited has signed a contract with United States-based MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a ready-to-use 250mg/50mL single-use vial in the United States.
Endo is to commercialise the FDA-approved product via its Par Sterile Products business and is expected to commence shipping this summer.
Scott Sims, SVP and General Manager, Injectable Solutions & Generics at Endo, said, 'Hospital providers have told us what they need--ready-to-use medications that allow them to focus on patients rather than preparation. Through this partnership with MAIA Pharmaceuticals, we are proud to answer that call with the only ready-to-use liquid format of bivalirudin.'
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data